Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.21M | $0.00 | $0.00 | $0.00 | $2.98M | $4.63M |
| Revenue growth | — | -100.0% | — | — | — | 55.3% |
| Operating income | -$932K | -$84.5M | -$117M | -$205M | -$202M | -$208M |
| Operating margin | -17.9% | — | — | — | -6787.4% | -4498.1% |
| Net income | -$3.41M | -$165M | -$122M | -$198M | -$196M | -$201M |
| Net margin | -65.5% | — | — | — | -6566.6% | -4342.4% |
| EPS (diluted) | -$1.91 | -$14.19 | -$4.19 | -$2.18 | -$1.65 | -$1.35 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.54M | -$34.1M | -$132M | -$165M | -$123M | -$163M |
| Capital expenditures | $639K | $4.15M | $16.1M | $8.72M | $7.29M | $4.53M |
| Free cash flow | -$6.18M | -$38.2M | -$148M | -$174M | -$130M | -$167M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $37.0M | $185M | $188M | $41.6M | $182M | $63.0M |
| Total assets | — | $302M | $360M | $194M | $298M | $343M |
| Total liabilities | — | $62.3M | $44.0M | $60.8M | $144M | $222M |
| Shareholders' equity | $2.34M | -$156M | $316M | $133M | $153M | $121M |
| Retained earnings | — | -$171M | -$293M | -$491M | -$687M | -$888M |
| Shares (wtd avg diluted) | 2.64M | 13.0M | 33.9M | 91.0M | 119M | 149M |
Every figure is extracted from Prime Medicine, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.